| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Departments of Pharmacological and Physiological Science and Internal Medicine, Saint Louis University School of Medicine, St. Louis, Missouri 63104
Previously, we reported that in the isolated perfused rabbit lung, red blood cells (RBCs) obtained from either rabbits or healthy humans were a required component of the perfusate to unmask evidence of nitric oxide (NO) participation in regulation of the pulmonary circulation. In addition, we found that mechanical deformation of rabbit and healthy human RBCs released ATP, a known agonist for enhanced NO synthesis. In contrast, RBCs obtained from patients with cystic fibrosis (CF) did not release ATP in response to mechanical deformation. The coexistence of airway disease and alveolar hypoxia in patients with CF precluded the drawing of conclusions relating a defect in RBC ATP release with the pulmonary hypertension associated with CF. Airway disease and alveolar hypoxia are not, however, features of primary pulmonary hypertension (PPH), a human condition of unknown etiology. We postulated that a defect in NO generation might contribute to the increased pulmonary vascular resistance in PPH, and as a first step, we hypothesized that RBCs obtained from patients with PPH would not release ATP. In contrast to RBCs of healthy humans, when RBCs of PPH patients were passed through filters (average pore size 12, 8, or 5 µm), ATP was not released and the RBCs exhibited reduced deformability. Moreover, when incubated with the active cAMP analogue, Sp-cAMP (100 µM), an activator of the CF transmembrane conductance regulator, ATP was not released. These results demonstrate that RBCs obtained from patients with PPH fail to release ATP whether the stimulus is mechanical or pharmacological. Thus, failure of RBCs to release ATP in patients with PPH might be a major pathogenetic factor that accounts for the heretofore unknown etiology of their pulmonary hypertension.
Key Words: erythrocyte • lungs • cystic fibrosis • prostacyclin • epoprostenol
This article has been cited by other articles:
|
|
 |
|
  M. P. Abbracchio, G. Burnstock, J.-M. Boeynaems, E. A. Barnard, J. L. Boyer, C. Kennedy, G. E. Knight, M. Fumagalli, C. Gachet, K. A. Jacobson, et al. International Union of Pharmacology LVIII: Update on the P2Y G Protein-Coupled Nucleotide Receptors: From Molecular Mechanisms and Pathophysiology to Therapy Pharmacol. Rev., September 1, 2006; 58(3): 281 - 341. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Burnstock Pathophysiology and therapeutic potential of purinergic signaling. Pharmacol. Rev., March 1, 2006; 58(1): 58 - 86. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Wang, G. Olivecrona, M. Gotberg, M. L. Olsson, M. S. Winzell, and D. Erlinge ADP Acting on P2Y13 Receptors Is a Negative Feedback Pathway for ATP Release From Human Red Blood Cells Circ. Res., February 4, 2005; 96(2): 189 - 196. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. F. Hoffman, A. Dodson, A. Wickrema, and S. D. Dib-Hajj Tetrodotoxin-sensitive Na+ channels and muscarinic and purinergic receptors identified in human erythroid progenitor cells and red blood cell ghosts PNAS, August 17, 2004; 101(33): 12370 - 12374. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. S. Sprague, J. J. Olearczyk, D. M. Spence, A. H. Stephenson, R. W. Sprung, and A. J. Lonigro Extracellular ATP signaling in the rabbit lung: erythrocytes as determinants of vascular resistance Am J Physiol Heart Circ Physiol, July 11, 2003; 285(2): H693 - H700. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Zhao, E. W. Inscho, M. Bondlela, J. R. Falck, and J. D. Imig The CYP450 hydroxylase pathway contributes to P2X receptor-mediated afferent arteriolar vasoconstriction Am J Physiol Heart Circ Physiol, November 1, 2001; 281(5): H2089 - H2096. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
